H
Hira Imad Cheema Institution-verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Researcher
faculty
5 h-index
15 pubs
292 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Hira Imad Cheema's research focuses on clinical outcomes and treatment strategies for various medical conditions, with a significant emphasis on hematologic malignancies and gastrointestinal disorders. Cheema has investigated the efficacy and safety of novel therapies, such as teclistamab, in treating relapsed multiple myeloma and associated complications like Cytomegalovirus reactivation and idiopathic immune thrombocytopenia. Their work also examines the impact of minimal residual disease status on clinical outcomes in multiple myeloma, considering molecular subgroups. In the realm of gastrointestinal health, Cheema has explored advances in the endoscopic management of gastric neoplasms and reviewed evidence regarding methotrexate's effect on liver fibrosis. Additionally, their research includes case reports on duodenal diagnoses and the management of Heyde's Syndrome. Cheema collaborates with several researchers at the University of Arkansas for Medical Sciences, including Ramya Bachu and Tanvi H Patel, with whom they have co-authored multiple publications.
Metrics
- h-index: 5
- Publications: 15
- Citations: 292
Selected Publications
-
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)
-
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024)
-
A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma (2024)
-
Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm (2024)
-
A Case of Duodenal “Spot” Diagnosis (2022)
Collaboration Network
Top Collaborators
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
6 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Showing 5 of 6 shared publications
Ramya Bachu
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Samer Al Hadidi
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Maurizio Zangari
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Carolina Schinke
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Anup Kumar Trikannad
Winthrop Rockefeller Foundation (US)
4 shared publications
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Trilok Shrivastava
Winthrop Rockefeller Foundation
4 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Frits van Rhee
University of Arkansas for Medical Sciences
4 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Asis Shrestha
University of Arkansas for Medical Sciences (US)
4 shared publications
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Tanvi Patel
Winthrop Rockefeller Foundation (US)
3 shared publications
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Syed Naqvi
University of Arkansas for Medical Sciences
3 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Cem Cengız
TOBB University of Economics and Technology
2 shared publications
In database
- Recent advances in endoscopic management of gastric neoplasms
- Resection of subepithelial lesions by a novel technique: “Band endoscopic full-thickness resection”
Sumant Inamdar
University of Arkansas for Medical Sciences (US)
2 shared publications
- Recent advances in endoscopic management of gastric neoplasms
- Resection of subepithelial lesions by a novel technique: “Band endoscopic full-thickness resection”
Benjamin Tharian
Bayfront Medical Center (US)
2 shared publications
- Recent advances in endoscopic management of gastric neoplasms
- Resection of subepithelial lesions by a novel technique: “Band endoscopic full-thickness resection”
Sruthi Vellanki
University of Arkansas for Medical Sciences (US)
2 shared publications
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
Similar Researchers
Based on overlapping research topics
Samer S.A. Al Hadidi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Munawar Hussain .
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Nishanth Thalambedu
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Jaskirat Sethi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Naveen Yarlagadda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Abdul Rafae
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation